Navigation Links
Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
Date:9/6/2007

NEW YORK, Sept. 6 /PRNewswire/ -- Globally, approximately 418 billion people are currently infected with hepatitis, and the unrecognized importance, danger, and costs of hepatitis in the 21st century cannot be understated or underestimated, according to Global Hepatitis Strategies, a new report by Kalorama Information.

Paradoxically, despite the obvious crisis, world governments are not taking the necessary steps to contain hepatitis. Yet the incidence and prevalence of hepatitis have begun to rise in certain parts of the global community, and even industrialized nations are lacking hepatitis control policies. Moreover, there is a greater crisis in hepatitis screening, diagnosis, and treatment emerging, particularly in those areas where HIV/AIDS is becoming more prevalent.

Kalorama Information estimates that the theoretical global market for all hepatitis testing products and therapeutics in 2006, assuming that aggressive screening were to be conducted, would be $3.3 trillion, with the western Pacific and southeast Asia showing the greatest need. However, the estimated realistic market potential for the various global regions for 2006, based on their currently reported hepatitis status and pricing structure, fell far short, reaching just $326 million.

"The strategic concept of hepatitis diagnosis and therapy is one of the most insufficiently recognized areas that the healthcare industry has ever seen," notes Kenneth. G. Krul, PhD, the report's author. "Governments, with the exception of a limited few, seem unable or unwilling to devise comprehensive hepatitis containment and prevention policies. In order to cope with the challenges and opportunities of hepatitis diagnostics and therapeutics, companies must think on a global basis, focusing on three points for the development of strategy: potential market, epidemiology (hepatitis patient trends), and technology."

Global Hepatitis Strategies focuses on the factors that influence policy aspects of hepatitis, the options presented, the factors associated with strategic market development of hepatitis diagnostics and therapeutics, and prospects for the future. The report analyzes strategic market effects of epidemiology, market potential and technology, trends in epidemiology, and social/political attitudes towards hepatitis. This report can be purchased directly from Kalorama Information by visiting: https://www.kaloramainformation.com/Global-Hepatitis-Strategies-1517677. It is also available at MarketResearch.com.

About Kalorama Information

Kalorama Information supplies the latest in independent market research on medical markets. For more information, contact Tom Ehart at 240-747-3014 or tehart@marketresearch.com, or visit http://www.KaloramaInformation.com.


'/>"/>
SOURCE Kalorama Information
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Gala Biotech among companies sold for $3.3 billion
2. Is your brand worth billions?
3. Fiserv makes over $1 billion, but profits decline
4. GE completes $1.2 billion acquisition
5. $1.45 billion judgment against Morgan Stanley sends message revisit e-mail retention policies
6. Alzheimers drug market to hit $5.5 billion by 2009, study says
7. How a Midwestern girl became the CEO of a multi-billion-dollar software company
8. Billions with a B for R&D
9. Your Data: Silencing Hepatitis C Virus Replication With In Vitro Transcribed siRNAs
10. Southwestern lab selects Third Wave reagents for Hepatitis tests
11. Third Wave releases reagents for Hepatitis C testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):